Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective Trial
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
We aim to compare the augmentation of clozapine with ziprasidone or risperidone in a randomized, prospective manner.
Condition or disease
Schizophrenia, Schizoaffective Disorder
Drug: ziprasidoneDrug: risperidone
Partial response of schizophrenic psychoses to a monotherapy with clozapine is a frequent problem of clinical psychiatry. Current problems are treatment resistant positive and/or negative symptoms, as well as side effects. Therefore, different strategies of augmentations have been applied. Based on successful experiences in case reports and results of other work groups, we aim to compare the augmentation of clozapine with ziprasidone or risperidone in a randomized, prospective manner.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 70 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Treatment resistant schizophrenic or schizoaffective disorder under therapy with clozapine,
Age between 18 and 70,
No informed consent,
Intolerance with respect to ziprasidone or risperidone,
Contraindications with respect to these substances,